<DOC>
	<DOCNO>NCT01764009</DOCNO>
	<brief_summary>The objective present trial : - determine dose limit toxicity ( DLT ) , maximal tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) intramuscular electrotransferred Plasmid AMEP patient advance metastatic melanoma . - determine local general safety intramuscular electrotransferred Plasmid AMEP - evaluate efficacy intramuscular electrotransferred Plasmid AMEP</brief_summary>
	<brief_title>Safety Efficacy Intramuscular Electrotransfer Plasmid AMEP Patients Suffering From Advanced Metastatic Melanoma</brief_title>
	<detailed_description>In open-label , multicentre , dose escalation phase I study , successive cohort 3 patient suffer advanced metastatic melanoma electrotransferred increase dos Plasmid AMEP muscle . Treatment repeat every 28 day progression limit toxicity . Consecutive cohort 3 6 patient treat increase dos Plasmid AMEP three dose level : 0.25 mg , 1 mg 4 mg accord adapt 3+3 design . There intra-patient dose escalation .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Aged 18 year Patient histologically cytologically confirm melanoma Patient unresectable advanced metastatic ( stage III IV ) melanoma Patient progressive melanoma ( BRAF status permit ) respond intolerant previous treatment , include patient asymptomatic rapidly progressive brain metastasis . Patient minimum one measurable lesion accord RECIST guideline 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Patient give write informed consent Patient eligible curative treatment and/or palliative treatment demonstrate efficacy , include current treatment brain metastasis , include available BRAF inhibitor indicate patient carry BRAF mutate tumour applicable . Patient history cancer within five year enrollment ( except cure basal cell carcinoma cervical cancer situ ) Patient inadequate organ function , define : Platelet count &lt; 75.103 /L ( &gt; grade 2 NCI CTCAE ) Absolute neutrophil count &lt; 1.109 /L ( &gt; grade 2 ) Hemoglobin &lt; 9 g/dL INR increase prolonged activate partial thromboplastin time ( aPTT ) upper limit normal ( ULN ) ( ≥ grade 1 ) Creatinine clearance &lt; 60 mL/min ( Cockcroft Gault formula ) ( ≥ grade 2 ) Patient ALT &gt; 3 ULN ( ≥ grade 2 ) patient symptomatic liver metastasis ALT &gt; 5 ULN ( &gt; grade 2 ) Serum Total Bilirubin &gt; 1.5 ULN ( ≥ grade 2 ) ; Patient Gilbert 's syndrome could include hyperbilirubinemia ≤ 3 ULN Not medically control coagulation disorder ( i.e hemophilia , protein C S deficiency… ) Patient electronic pacemaker , defibrillator , implant electronic device Any cardiac dysrhythmia ( &gt; grade 2 ) ( i.e significant ventricular arrhythmia persistent ventricular tachycardia and/or ventricular fibrillation ; severe conduction disorder atrioventricular block 2 3 , sinoatrial block ) Recent ( less 6 month ) acute vascular disease ( i.e stroke , myocardial infarction ) Arterial vascular disorder ≥ grade 2 Serious , nonhealed wound , ulcer bone fracture Significant traumatic injury within 28 day prior study treatment start anticipation need major surgery study treatment Evidence ongoing active viral bacterial infection ( i.e bacterial infection require IV antibiotic ) Patient life expectancy le 3 month Prior systemic therapy antineoplastic treatment within last 4 week , include radiotherapy surgery Patients participate another clinical trial last 30 day prior enrolment present clinical trial Man woman childbearing age without effective contraception method study 3 month last administration Plasmid AMEP ( i.e oral contraception intrauterine device woman ; i.e condom man ) Pregnant nurse woman Any significant disease , include psychiatric neuromuscular disease , may affect proper evaluation safety efficacy may affect ability give inform consent Patients unwilling unable comply protocol requirement schedule visit For contrast enhance ultrasound ( CEUS ) : know contraindication SonoVue describe summary product characteristic ( i.e cardiac pulmonary history , hypersensitivity sulphur hexafluoride component SonoVue ) For part II : prophylactic phenytoin combination dacarbazine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Advanced Melanoma</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Melanoma Stage III IV</keyword>
</DOC>